{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:47:00Z","timestamp":1749628020342},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das Pyoderma gangraenosum (PG) geh\u00f6rt zu den <jats:italic>orphan diseases<\/jats:italic>, deren Erforschung sich lediglich auf einzelne, randomisierte, multizentrische sowie retrospektive Studien st\u00fctzen kann und \u00fcberwiegend auf Fallserien an kleinen Patientenkollektiven beruht. Die Therapie basiert neben topischen und lokal intral\u00e4sionalen Therapieoptionen, bei initialem und leichtem Krankheitsverlauf, insbesondere auf der Gabe von Systemtherapeutika. Diese beinhaltet neben den systemischen Glukokortikosteroiden und Ciclosporin\u00a0A (CsA) auch Biologika wie intraven\u00f6ses Immunglobulin G (IVIG), die TNF\u03b1\u2010Inhibitoren Infliximab, Adalimumab und Etanercept, den IL\u201012\/23\u2010Antik\u00f6rper Ustekinumab, den Interleukin\u20101\u2010Rezeptorantagonist Anakinra und den Interleukin\u20101\u03b2\u2010Antik\u00f6rper Canakinumab. Die besten evidenzbasierten Studienergebnisse liegen zu CsA, Prednisolon und Infliximab vor, letzteres insbesondere bei gleichzeitigem Vorliegen einer Colitis ulcerosa oder eines Morbus Crohn. Kleinere Fallserien liegen f\u00fcr ein Ansprechen auf IVIG und Canakinumab vor. Obwohl die Erstbeschreibung durch Brocq fast 100 Jahren zur\u00fcckliegt und die Behandlungsnotwendigkeit des PG fr\u00fch erkannt wurde, bleibt die Therapie des PG bis heute eine klinische Herausforderung. Weitere klinische Studien, insbesondere an dringend erforderlichen gr\u00f6\u00dferen Patientenkollektiven, ein besseres Verst\u00e4ndnis der \u00c4tiopathogenese, der Einsatz moderner zielgerichteter Therapien mit h\u00f6herer Effektivit\u00e4t und geringerer Nebenwirkungsrate als die konventionellen Immunsuppressiva Prednisolon und CsA lassen trotz des seltenen aber schwerwiegenden Krankheitsbildes eine Verbesserung der Therapieoptionen in Zukunft erwarten.<\/jats:p>","DOI":"10.1111\/ddg.13173_g","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T15:34:55Z","timestamp":1485876895000},"page":"34-41","source":"Crossref","is-referenced-by-count":10,"title":["Therapieoptionen beim Pyoderma gangraenosum"],"prefix":"10.1111","volume":"15","author":[{"given":"Sven R.","family":"Quist","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Dermatologie und Venerologie Otto\u2010von\u2010Guericke Universit\u00e4t  Magdeburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luise","family":"Kraas","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie und Venerologie Otto\u2010von\u2010Guericke Universit\u00e4t  Magdeburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-136"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.030"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104515"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ddg.12822","article-title":"Pain and pain management in dermatology","volume":"13","author":"Beiteke U","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/ddg.12401","article-title":"Diagnostic criteria for pyoderma gangrenosum: results of a survey among dermatologic wound experts in Germany","volume":"12","author":"Al Ghazal P","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v1.i2.74"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00344.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.8.961"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14037"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12394"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/ddg.12830","article-title":"Pyoderma gangrenosum\u2010like necrotizing panniculitis associated with alpha\u20101 antitrypsin deficiency: a lethal course","volume":"13","author":"Vigl K","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12585"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.03133.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2010.00725.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347541201600503"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02280.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/095466301750163518"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.06.003"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198512000-00011"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12361"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-011-2269-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.009"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.009"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2005.05022.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03199.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa \u2013 rapid response to canakinumab (anti\u2010IL\u20101beta)","volume":"23","author":"Jaeger T","year":"2013","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12585"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.045"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034075"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2762-2"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07581.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0006-6"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0540"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08217.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08433.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.328"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.168"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13173_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13173_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:56:47Z","timestamp":1696247807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13173_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/ddg.13173_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13173_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}